Editorial Board Member - JMBS
Professor Esam Z. Dajani, Ph.D., FACG is the founder and president of International Drug Development Consultants (IDDC) Corporation, a Contract Research Organization (CRO) which provides scientific consulting services to pharmaceutical companies, law firms, and governmental agencies. The scope of the consulting service includes clinical pharmacology, toxicology, drug development and regulatory affairs. He has directed worldwide clinical research and development at major pharmaceutical companies. He led the research teams that discovered and developed misoprostol (Cytotec), an anti-ulcer drug. Since 1980, he held continuous academic appointments in pharmacology and in medicine. He is currently serving as Adjunct Professor of Medicine at Loyola University-Chicago. He taught pharmacology and toxicology to medical, dental and pharmacy students. He has research interests in clinical pharmacology, gastrointestinal pharmacology, central nervous system pharmacology, prostaglandins, non-steroidal anti-inflammatory drugs (NSAIDs), growth hormones (e.g., epidermal growth factor), cannabinoids and narcotic analgesics.
Other Editorial Board Members - JMBS
Department of Internal Medicine and Infectious Diseases
University of Coimbra
School Medicine Pharmacy and Health
University of Massachusetts Medical School
Department of Anatomy & Embryology